Effect of CCL21/CCR7 chemokine axis on cell growth
CCL21/CCR7 chemokine axis can affect cell proliferation by mediating
different signaling pathways. Early studies have shown that CCL21 can
affect the biological activity of hematopoietic progenitor cells by
inhibiting their proliferation. Additionally, CCL21/CCR7 chemokine axis
can also affect the proliferation of glomerular mesangial cells,
CD4+ T cells, CD8+T cells and CD34+cells in bone marrow through different signals (Zhang et al., 2016). It
was also proved that CCL21/CCR7 chemokine axis inhibits T cell
proliferation by slowing down the degradation of cyclin dependent kinase
(CDK) inhibitors and down-regulating the activity of CDK1 (Kuwabara et
al., 2012). A recent investigations found that CCL21/CCR7
chemokine axis stimulated the
proliferation of DCs in bone marrow through phosphorylating NF-ĸB65.
These results provide a new entry point for studying the function of
CCL21/CCR7 chemokine axis in terms of proliferation (Korbecki et al.,
2020, Li et al., 2020).
Other functions of
CCL21/CCR7 chemokine axis
In addition to the above functions, CCL21/CCR7
chemokine axis has a certain effects
on cell differentiation, survival, endocytosis, migration rate and
invasion ability. Studies have suggestted that the binding of CCL21 and
CCR7 can significantly affect the internal structure and migration rate
of renal DCs and blood T cells (Luo
et al., 2020, Legler et al., 2016).
And different concentrations of CCL21 produced different chemotactic
rates for renal DCs and blood T cells. The functional diversity of
CCL21/CCR7 chemokine axis in the immune process also provides the basis
for participating in the occurrence and development of autoimmune
diseases. With the continuous in-depth study of CCL21/CCR7 chemokine
axis, the role of CCL21/CCR7 chemokine axis has attracted more and more
attention from domestic and foreign scholars in autoimmune diseases
(Rong et al., 2017, Zlotnik et al., 2012, Sokol et al., 2015).